MedTrace Logo

Effect of Science Research Wellness Ndo1 on Glycaemia in Adults With Pre-diabetes

NCT06897462 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-07-24

No results posted yet for this study

Summary

The objective of this study is to test the effect of 12 weeks of supplementation SRW Ndo1 on metabolic health and general health in adults with prediabetes. The primary question it aims to answer are:

* How does SRW Ndo1 affect the Haemoglobin A1C (HbA1C) test outcome for adult individuals?
* How does SRW Ndo1 affect the body measures and blood pressures of adult individuals?

Investigators will compare the supplement to a placebo (a look-alike substance that contains no supplement) to see if SRW Ndo1 works to support normal blood sugar metabolism.

Participants will:

* Take supplement SRW Ndo1, two capsules a day for 12 weeks.
* Be asked to refrain from changing their diet and lifestyle drastically during the study and to refrain from starting new health supplements during the study.
* Visit the clinic at the start and the end of intervention for a blood test (8 hour fasting required prior to test)
* Keep a diary of their symptoms or adverse events during intervention.

Conditions

Interventions

DIETARY_SUPPLEMENT

SRW Ndo1

The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).

Sponsors & Collaborators

  • Wellizen Australia

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2025-07-01
Completion
2025-07-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897462 on ClinicalTrials.gov